Olink to provide proteomics data from 53,000 UK Biobank participants
We are proud to announce that the Olink® Explore 1536 platform, utilizing Next Generation Sequencing (NGS) as read-out, will be used in a project to measure plasma protein concentration in 53,000 individuals from the UK Biobank, one of the world’s largest genetic resources. The project is funded by a consortium of ten biopharmaceutical companies.
This large-scale proteomics study will further enhance previous commitments from several consortium members on genomic analyses of the 500,000 volunteers in the UK Biobank resource, with the ultimate goals of developing a better understanding of disease biology and more effective therapies. The consortium will analyze 56,000 samples from 53,000 participants starting in 2021, making over 7.3 million protein measurements available in a matter of months.
The ten biopharmaceutical companies involved in the consortium are: Amgen, AstraZeneca, Bristol Myers Squibb, Biogen, Genentech (a member of the Roche Group), GlaxoSmithKline (GSK), Janssen, Pfizer Inc, Regeneron and Takeda Pharmaceutical Co. Ltd.
Read our full press release using the link button below. You can also read a press release about this project that was published by UK Biobank here